| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Division of Hematology and Oncology, Department of Medicine, Case Western Reserve University, Cleveland, OH
Requests for Reprints:Lili Liu, Division of Hematology and Oncology, Department of Medicine, Case Western Reserve University, 10900 Euclid Avenue, BRB-3, Cleveland, OH 44106. Phone: (216) 368-5194; Fax: (216) 368-1166. E-mail: LxL32{at}po.cwru.edu
Methoxyamine (MX) has been shown to potentiate the antitumor effect of temozolomide (TMZ) in human tumor xenograft models. This potentiation is due to the reactivity of MX with apurinic/pyrimidinic (AP) sites in DNA, which are formed following DNA glycosylase removal of TMZ-induced methyl-purine adducts. MX-bound AP sites cannot be further processed by base excision repair (BER), resulting in cell death. On the basis of this finding, we investigated in vivo whether MX enhanced therapeutic efficacy of other agents, such as 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) that generates AP sites during DNA repair. Nude mice carrying human colon tumor xenografts, HCT116 and HCT116-Ch3, were treated by a single injection (i.p) of BCNU alone (30 mg/kg) or MX (2 mg/kg) combined with BCNU. The effect on tumor growth of BCNU alone was very moderate. Combined administration of MX and BCNU produced significant inhibition of tumor growth. Tumor growth delays were 14 ± 3 days in HCT116 and 16 ± 2 days in HCT116-Ch3 tumors, respectively (P < 0.05 versus control or BCNU alone groups). Similar results were also observed in SW480 and DLD1 tumors. Importantly, no systemic toxicity was noted with BCNU and MX. In contrast, BCNU (at dose of 25 mg/kg) combined with O6-benzylguanine (BG), an inhibitor of O6-alkylguanine-DNA alkyltransferase (AGT) being tested in clinical trials, caused toxic death in all treated mice. However, a lower dose BCNU (10 mg/kg) combined with BG and MX had significant antitumor effect without toxic death. Thus, targeting BER with MX is a promising strategy to improve the antitumor activity of BCNU and perhaps other DNA-damaging agents.
Key Words: Methoxyamine • AP sites • DNA repair • xenograft
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Grant support:Public Health Service Grants RO1CA86357, RO1CA82292, and CA43703.
Received 4/ 3/03; revised 6/ 4/03; accepted 6/27/03.
This article has been cited by other articles:
|
|
 |
|
  L. A. Seiple, J. H. Cardellina II, R. Akee, and J. T. Stivers Potent Inhibition of Human Apurinic/Apyrimidinic Endonuclease 1 by Arylstibonic Acids Mol. Pharmacol., March 1, 2008; 73(3): 669 - 677. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Pommier DNA Repair Modulators as Anticancer Agents ASCO Educational Book, January 1, 2008; 2008(1): 128 - 133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sanada, M. Hidaka, Y. Takagi, T. Y. Takano, Y. Nakatsu, T. Tsuzuki, and M. Sekiguchi Modes of actions of two types of anti-neoplastic drugs, dacarbazine and ACNU, to induce apoptosis Carcinogenesis, December 1, 2007; 28(12): 2657 - 2663. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Yan, A. Bulgar, Y. Miao, V. Mahajan, J. R. Donze, S. L. Gerson, and L. Liu Combined Treatment with Temozolomide and Methoxyamine: Blocking Apurininc/Pyrimidinic Site Repair Coupled with Targeting Topoisomerase II{alpha} Clin. Cancer Res., March 1, 2007; 13(5): 1532 - 1539. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Yan, Y. Seo, J. E. Schupp, X. Zeng, A. B. Desai, and T. J. Kinsella Methoxyamine potentiates iododeoxyuridine-induced radiosensitization by altering cell cycle kinetics and enhancing senescence. Mol. Cancer Ther., April 1, 2006; 5(4): 893 - 902. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Liu and S. L. Gerson Targeted Modulation of MGMT: Clinical Implications Clin. Cancer Res., January 15, 2006; 12(2): 328 - 331. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Paik, T. Duncan, T. Lindahl, and B. Sedgwick Sensitization of Human Carcinoma Cells to Alkylating Agents by Small Interfering RNA Suppression of 3-Alkyladenine-DNA Glycosylase Cancer Res., October 15, 2005; 65(22): 10472 - 10477. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Cai, Y. Xu, R. J. Cooper, M. J. Ferkowicz, J. R. Hartwell, K. E. Pollok, and M. R. Kelley Mitochondrial Targeting of Human O6-Methylguanine DNA Methyltransferase Protects against Cell Killing by Chemotherapeutic Alkylating Agents Cancer Res., April 15, 2005; 65(8): 3319 - 3327. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rinne, D. Caldwell, and M. R. Kelley Transient adenoviral N-methylpurine DNA glycosylase overexpression imparts chemotherapeutic sensitivity to human breast cancer cells Mol. Cancer Ther., August 1, 2004; 3(8): 955 - 967. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
